2026-10-25
COMPASS Pathways clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,813 +0.55%
S&P 7,744 +0.28%
GOLD $4,041 −0.27%
BTC $80,068 −1.48%
VIX 17.02 +0.65%
latest tape · as of 10:09 UTC
The Screen · Healthcare · Medical Care Facilities
COMPASS Pathways plc
CMPS · Nasdaq · USD · Market cap $1.6B · 156 employees
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
Not yet scored11.81 USD
Price as of 27 Oct 2026Daily close, not a live quote
Screened 2026-10-27 · the tape above runs as of 10:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price11.81 USD at the 27 Oct 2026 close
- Our ratingFair value, current read markdown
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.57)
- Last reviewed27 Oct 2026 (2 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 11.81 against the desk's fair-value range, base estimate 21.00, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.57, read 2026-10-28
- Ethical screen not yet scored
Price11.81 USD
Fair value21.00
Ethical score95.2/100
RatingFAIR VALUE
Our investment reviews on this name
2026-10-02Read Markdown13.09-9.8% to today ✓Markup gives way to Markdown after an 8% rise in 13 weeks
2026-07-02Read Markup12.11-2.5% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markdown label.
COMPASS Pathways plc holds its Markdown at $11.81. The statistical read favours the sellers, held for 76 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the sellers, held for 76 days |
| Price at the screen | $11.81 |
| Valuation | N/A trailing · -8.24 forward price to earnings |
| Values screen | Not scored · score 95.2 |
| Beta | 2.56 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 2.40% | Below 33% | Interest-bearing debt is just 2.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 10.27% | Below 33% | Cash held in interest-bearing accounts and securities is 10.3% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
COMPASS Pathways clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
COMPASS Pathways clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 2%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads FAIR VALUE: it trades at roughly a 78% discount to our $21.00 fair value.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. A 77.8% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Strong Buy. The average target sits +78% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPsychedelic Depression Drug Still Below Its True Worth
Imagine a patient stuck on antidepressants that stopped working years ago. COMPASS Pathways is running the late-stage trial that could deliver a new option using synthetic psilocybin. The shares sit at $12.35 against a $21 fair value, a 70 percent margin of safety, while fifteen analysts carry a strong-buy consensus and the same $21 median target.
The business is still pre-revenue with a forward P/E of minus 11.4 times, zero profit margin and return on equity of minus 68 percent. Those numbers are normal for a Phase III biotech, yet the ethical screen clears because the aim is treatment-resistant depression rather than any harmful product.
Risk sits in the usual clinical and regulatory hurdles plus the chance that peak earnings never arrive if the data disappoint. Currency moves and dilution from future raises add further pressure. Analysis, not advice.
| Forward P/E | -8.2x |
| EPS, trailing | -3.76 |
| EPS, forward | -1.43 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -319.1%not currently earning a positive return on equity |
| FCF yield | 15.28% |
| Debt to equity | 0.65moderate, manageable leverage |
| Current ratio | 1.30adequate liquidity, worth monitoring |
| Beta | 2.56much more volatile than the market |
| Short interest, float | 0.12% |
| 52-week range | 4.88 - 15.87 |
| Market cap | $1.6B |
| Employees | 156 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCMPS trades on Nasdaq (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-28
Markdown $11.81
+1.6% Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-10-21
Markdown $11.62
-3.2% Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 6% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-10-14
Markdown $12.00
-8.3% Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-10-02
Markdown · changed $13.09
-6.6% Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-08-25
Markup $14.01
+13.4% Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.4% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-07-25
Markup $12.35
+2.0% Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-07-18
Markup $12.11
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-07-03
Markup $12.11
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02
Markup $12.11
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances Yahoo Finance · 8d ago
- COMPASS Pathways (CMPS) Stock May Trade At A Premium After Positive Phase 3 Results Yahoo Finance · 11d ago
- Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day Yahoo Finance · 15d ago
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance · 27d ago
- COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III Progress Yahoo Finance · 28d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
AGLagilon health, inc.
SNDASonida Senior Living, Inc.
PNTGThe Pennant Group, Inc.
HCSGHealthcare Services Group, Inc.
NUTXNutex Health Inc.
ARDTArdent Health, Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-26 | LOXAM TERI | Chief Financial Officer | 75,000 | · | |
| 2026-03-26 | NATH KABIR | Chief Executive Officer | 175,000 | · | |
| 2025-03-11 | LOXAM TERI | Chief Financial Officer | 25,000 | · | |
| 2024-10-24 | GOLDSMITH GEORGE JAY | Beneficial Owner of more than 10% of a Class of Security | 776,565 | $4,993,313 | |
| 2024-10-24 | MALIEVSKAIA EKATERINA | Beneficial Owner of more than 10% of a Class of Security | 1,553,130 | $9,986,626 | |
| 2024-09-26 | ATAI LIFE SCIENCES NV | Beneficial Owner of more than 10% of a Class of Security | 2,660,000 | $16,093,000 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.65 | +15.6% | · | $1,156 | +15.6% |
| 2 months | $5.53 | +101.8% | · | $2,018 | +101.8% |
| 3 months | $6.63 | +68.3% | · | $1,683 | +68.3% |
| 6 months | $6.94 | +60.8% | · | $1,608 | +60.8% |
| 1 year | $4.76 | +134.4% | · | $2,344 | +134.4% |
| 2 years | $6.55 | +70.4% | · | $1,704 | +70.4% |
| 3 years | $7.84 | +42.3% | · | $1,423 | +42.3% |
| 5 years | $39.68 | -71.9% | · | $281 | -71.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CMPS does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.